Jean Pascal Tranie

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

Allogenica is a Lyon-based biotechnology company specialized in the development of an emerging class of cancer therapy, called CAR-T cells (Chimeric Antigen Receptor T-cells). Allogenica has developed a bioproduction platform that relies on the manipulation of hematopoietic stem cells and their derivatives with the aim of developing allogenic "off-the-shelf" CAR-T cells. Allogenica will offer the next-generation cancer treatment ready to use, at low cost and safer than current treatments, in order to treat all patients who need it. The start-up is based in Cancer Research Center of Lyon/Centre Léon Bérard.

Bringing life to life. POLYGON Therapeutics aims to address unmet therapeutic needs through innovative breakthrough approaches. Within its first therapeutic development program EMOTION, POLYGON aspires to transform cardiovascular diseases care.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France).

WhiteLab Genomics is a TechBio company dedicated to unleashing the full power of genomic medicine with Artificial Intelligence. Founded in 2019 and backed by Y Combinator and the French Tech 2030 program, WhiteLab operates at the intersection of AI, computational biology, and structural biology, with offices in Paris, Boston, and Montréal. WhiteLab’s proprietary AI platform enables the rational design and optimization of delivery systems including viral and non-viral vectors, as well as RNA and DNA payloads. The company supports partners across a wide range of therapeutic areas, including but not limited to oncology, neurology, ophthalmology, auditory disorders, and rare diseases. WhiteLab’s mission is to unleash the potential of genomic medicine through advanced artificial intelligence, empowering scientists to design safer, more effective therapies from discovery through preclinical stages. WhiteLab collaborates with leading companies, including Sanofi, Cytiva and Debiopharm, and benefits from a strong network of top-tier academic partners such as the Brain Institute (ICM), the Vision Institute, the University of Massachusetts, and Genethon.

Born from a collaboration between leading expertise in computational biology (genomic sequence analysis) and advanced immune validation technologies developed at the Institut Curie, Cereus delivers what current immunotherapies cannot: a scalable, off-the-shelf vaccine built on truly tumor-specific antigens discovered in the dark genome

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

Allogenica is a Lyon-based biotechnology company specialized in the development of an emerging class of cancer therapy, called CAR-T cells (Chimeric Antigen Receptor T-cells). Allogenica has developed a bioproduction platform that relies on the manipulation of hematopoietic stem cells and their derivatives with the aim of developing allogenic "off-the-shelf" CAR-T cells. Allogenica will offer the next-generation cancer treatment ready to use, at low cost and safer than current treatments, in order to treat all patients who need it. The start-up is based in Cancer Research Center of Lyon/Centre Léon Bérard.

Bringing life to life. POLYGON Therapeutics aims to address unmet therapeutic needs through innovative breakthrough approaches. Within its first therapeutic development program EMOTION, POLYGON aspires to transform cardiovascular diseases care.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.